Regeneron Pharmaceuticals Dividend
Dividend criteria checks 0/6
Regeneron Pharmaceuticals does not have a record of paying a dividend.
|Industry average yield||2.7%|
|Next dividend pay date||n/a|
|Ex dividend date||n/a|
|Dividend per share||US$0|
|Earnings per share||US$39.05|
|Dividend yield forecast in 3Y||0%|
Recent dividend updates
Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?Apr 17
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share PriceFeb 03
We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Stay On Top Of Its DebtJan 16
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 39% Undervaluation?Oct 28
Regeneron, Bayer Eylea gets FDA priority review for eye disorder in infantsOct 12
Regeneron Pharmaceuticals (NASDAQ:REGN) Could Easily Take On More DebtOct 10
Sanofi, Regeneron win FDA label expansion for Dupixent in chronic, skin conditionSep 29
Regeneron: Fortune Seems To Favor This Bold, Innovative PharmaSep 14
Regeneron says pivotal trials for less frequent Eylea injections reached main goalsSep 08
Regeneron: There Are Challenges But Growth To Resume In 2023Aug 25
Regeneron monoclonal antibody gets WHO recommendation for EbolaAug 19
Regeneron IPR hearing suggests Eylea patent may be in trouble - analystAug 11
Regeneron Pharmaceuticals Non-GAAP EPS of $9.77 beats by $1.02, revenue of $2.86B beats by $60MAug 03
Is Now The Time To Put Regeneron Pharmaceuticals (NASDAQ:REGN) On Your Watchlist?Jul 26
Regeneron Post COVID BolusJul 16
Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?Jul 08
FDA accepts Regeneron's application for Eylea extended regimen to treat diabetic blindnessJun 29
Regeneron Pharmaceuticals: Lack Of Appreciation For The Purchase Of LibtayoJun 21
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 47% Below Their Intrinsic Value EstimateJun 05
Regeneron's Growth Set To Slow, But Could Outperform Downbeat Consensus ForecastsMay 21
Dividend Yield vs Market
|Regeneron Pharmaceuticals Dividend Yield vs Market|
|Market Bottom 25% (US)||1.7%|
|Market Top 25% (US)||5.1%|
|Industry Average (Biotechs)||2.7%|
|Analyst forecast in 3 Years (REGN)||0%|
Notable Dividend: Unable to evaluate REGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate REGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
|Month||Dividend Per Share (annual)||Avg. Yield (%)|
Stable Dividend: Insufficient data to determine if REGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if REGN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as REGN has not reported any payouts.